ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 161 filers reported holding ARCUS BIOSCIENCES INC in Q1 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,739,435 | -6.4% | 375,456 | +5.9% | 1.31% | +9.3% |
| Q2 2023 | $7,199,692 | +34.4% | 354,490 | +20.7% | 1.20% | +16.6% |
| Q1 2023 | $5,356,103 | +8.6% | 293,646 | +23.1% | 1.03% | +7.9% |
| Q4 2022 | $4,931,808 | -17.0% | 238,482 | +5.0% | 0.95% | -18.5% |
| Q3 2022 | $5,939,000 | -24.8% | 227,032 | -27.2% | 1.17% | -26.5% |
| Q2 2022 | $7,901,000 | -26.0% | 311,782 | -7.9% | 1.59% | -16.0% |
| Q1 2022 | $10,682,000 | -6.8% | 338,480 | +19.5% | 1.90% | +9.9% |
| Q4 2021 | $11,462,000 | -55.5% | 283,210 | -61.7% | 1.72% | -19.5% |
| Q3 2021 | $25,769,000 | +39.2% | 739,010 | +9.6% | 2.14% | +43.1% |
| Q2 2021 | $18,515,000 | -23.3% | 674,260 | -21.5% | 1.50% | -18.1% |
| Q1 2021 | $24,127,000 | +7.9% | 859,210 | -0.2% | 1.83% | +16.1% |
| Q4 2020 | $22,356,000 | +41.3% | 861,160 | -6.7% | 1.58% | +15.8% |
| Q3 2020 | $15,817,000 | +336.2% | 922,800 | +253.3% | 1.36% | +95.4% |
| Q1 2020 | $3,626,000 | – | 261,213 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |